Human factor XIII as a normalization control for immunoassays

US9797902B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-9797902-B2
Application numberUS-201715492905-A
CountryUS
Kind codeB2
Filing dateApr 20, 2017
Priority dateJun 22, 2012
Publication dateOct 24, 2017
Grant dateOct 24, 2017

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

The present disclosure provides compositions and methods that are useful for normalizing the amount of signal detected in an assay, such as an immunoassay. The compositions and methods are useful for improving the accuracy of immunoassays, such as immunoassays that detect whether a subject is infected with a retrovirus such as HIV.

First claim

Opening claim text (preview).

What is claimed is: 1. A kit for determining whether a subject is infected with HIV or a stage of infection of a subject so infected, said kit comprising a normalization factor immobilized on a solid support, and a plurality of binding members, each binding member immobilized on a solid support, said plurality comprising: (i) anti-p24 antibody, (ii) HIV-1 envelope protein gp-160, (ii) HIV-2 SPOH (RVTAIEKYLQDQARLNSWGCAFRQVC (SEQ ID NO:5)), and (iv) HIV-O AFR (LNQQRLLNSWGCKGRLVCYTSV (SEQ ID NO:2)); said solid supports further bearing differentiation parameters selected such that all said supports bearing any one binding member of said plurality are differentiable from all said supports bearing other binding members of said plurality. 2. The kit of claim 1 , wherein the normalization factor does not bind an analyte from the biological sample. 3. The kit of claim 1 , wherein the normalization factor is hFXIII. 4. The kit of claim 1 , further comprising an antibody to human Factor XIII immobilized on a solid support. 5. The kit of claim 1 , further comprising tetramethylcadaverine rhodamine (TMRC) immobilized on a solid support. 6. The kit of claim 1 , wherein the solid supports are beads or magnetic beads.

Assignees

Inventors

Classifications

  • Protein-glutamine gamma-glutamyltransferase (2.3.2.13), i.e. transglutaminase or factor XIII · CPC title

  • Protein-glutamine gamma-glutamyltransferase (2.3.2.13), i.e. transglutaminase or factor XIII · CPC title

  • Improving reaction conditions or stability, e.g. by coating or irradiation of surface, by reduction of non-specific binding, by promotion of specific binding · CPC title

  • Enzymes or microbial cells immobilised on or in an inorganic carrier · CPC title

  • HIV or HTLV · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US9797902B2 cover?
The present disclosure provides compositions and methods that are useful for normalizing the amount of signal detected in an assay, such as an immunoassay. The compositions and methods are useful for improving the accuracy of immunoassays, such as immunoassays that detect whether a subject is infected with a retrovirus such as HIV.
Who is the assignee on this patent?
Bio Rad Laboratories Inc
What technology area does this patent fall under?
Primary CPC classification G01N33/54393. Mapped technology areas include Physics.
When was this patent published?
Publication date Tue Oct 24 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 1 related publication on this page (citations in our corpus or others sharing the same primary CPC).